Top > Search of International Patents > PEPTIDE HAVING ACCUMULATION SPECIFIC TO PANCREATIC CANCER, AND USE OF SAID PEPTIDE

PEPTIDE HAVING ACCUMULATION SPECIFIC TO PANCREATIC CANCER, AND USE OF SAID PEPTIDE

Foreign code F170009109
File No. (S2016-0035-N0)
Posted date Jun 23, 2017
Country WIPO
International application number 2016JP081287
International publication number WO 2017086090
Date of international filing Oct 21, 2016
Date of international publication May 26, 2017
Priority data
  • P2015-226228 (Nov 19, 2015) JP
Title PEPTIDE HAVING ACCUMULATION SPECIFIC TO PANCREATIC CANCER, AND USE OF SAID PEPTIDE
Abstract The present invention provides a novel peptide having specific accumulation that acts directly on pancreatic cancer cells and tissues. The present invention is a peptide of (a) or (b) below. (a) A peptide comprising an amino acid sequence that includes a sequence represented by any of SEQ ID NOS: 1, 2, 3, or 4. (b) A peptide having accumulation specific to pancreatic cancer, the peptide comprising an amino acid sequence that has 60% or greater identity with a sequence represented by any of SEQ ID NOS: 1, 2, 3, or 4.
Outline of related art and contending technology BACKGROUND ART
Pancreatic cancer (particularly, invasive pancreatic duct cancer) is, the mean survival time after diagnosis and about 6 months before, among the malignant tumors are known to be refractory. According to the publication of the population demographics Welfare, deaths a year-tumor is increasing year after year, statistically (2009 year) Heisei 21st a person 26,791. In addition, death of all cancer deaths from pancreatic cancer accounts for 9%, lung cancer, gastric cancer, colon cancer, hepatic cancer then in the second position 5. (1999 Year) national pancreatic cancer according to registered Surveillance, pancreatic cancer cases can be cut, in 39% of all cases. Further, 5 - year survival rate is as low as 13%.
Reason difficult to treat pancreatic cancer, early in the state of the subjective symptom is small, and is extremely difficult to provide early detection. Cancer progressing, abdominal pain, weight loss, the appearance of symptoms such as jaundice, to be found in many cases, in the majority of cases, already at the time of discovery obvious symptom expression when there is no adaptive surgery, surgery or makeshift was restricted to the treatment of advanced cancer state. In addition, another reason for such, or metastatic pancreatic cancer that is infiltrated from an early stage and it has the property of being easily. As for other reasons, in radiosurgery, retroperitoneal pancreas is located on the back side of many for intraperitoneal organs, pancreas only the affected area is exposed to the radiation and it is difficult to point. Therefore, the radiation treatment may, cause serious side effects is likely to, be applied outside of the choice of therapy.
Current, pancreatic cancer as a test or diagnostic method, for example, blood biochemical tests, abdominal ultrasound examination, endoscopic retrograde biliary contrast (Endoscopic retrograde cholangiopancreatography: ERCP) pancreatic inspection, in combination with computed tomography contrast agent (Computed Tomography: CT), magnetic resonance imaging (Magnetic resonance imaging: MRI), positron emission tomography (Positron Emission Tomography: PET) method (particularly, fluorodeoxyglucose (fluorodeoxy glucose: FDG) - PET method) and the inspection method of the like.
However, the peptide is utilized as a biomaterial in the trend in the medical field, Tat, penetratin, polyarginine such as a cell-membrane permeable peptide (cell-absorbable) is drawing attention. However, these peptides, tumor cells or normal cells or normal tissue and tumor tissue as well as the diffuse and non-selectively absorbed, target selection drug requires the delivery of the treatment of malignant tumors (Drag Delivery System) to apply the tool DDS, cause serious side effects in that it is difficult to use. In particular, worldwide Tat on a general-purpose experimental system such as a cell-membrane permeable (a cell-absorbable) peptide, the nature that gives rise to the liver has been known (for example, see non-patent document 1). On the other hand, the cyclic RGD, has been the only peptide pharmaceutical. Is cyclic RGD, or an existing blood vessel constituting the angiogenic vascular endothelial cells (and in some tumor cells) is highly expressed in reported αv β3 which targets integrin, upregulation of vascular permeability due to its action point, without a simultaneous combination alone in the form of other pharmaceutical and imaging agents and have been applied as DDS (for example, see Patent Document 1.).
Scope of claims (In Japanese)[請求項1]
以下の(a)又は(b)のペプチド。
(a)配列番号1、2、3、4のいずれかで表される配列を含むアミノ酸配列からなるペプチド、
(b)配列番号1、2、3、4のいずれかで表される配列と同一性が60%以上である配列を含むアミノ酸配列からなり、且つ、膵癌に特異的な集積性を有するペプチド
[請求項2]
L-アミノ酸からなるペプチドである請求項1に記載のペプチド。
[請求項3]
請求項1又は2に記載のペプチドをコードすることを特徴とする核酸。
[請求項4]
請求項3に記載の核酸を含むことを特徴とするベクター。
[請求項5]
請求項1又は2に記載のペプチドを含むことを特徴とするキャリア。
[請求項6]
さらに、標識物質又は修飾物質を備える請求項5に記載のキャリア。
[請求項7]
前記標識物質が、安定同位体、放射性同位体又は蛍光物質である請求項6に記載のキャリア。
[請求項8]
前記修飾物質が、糖鎖又はポリエチレングリコールである請求項6又は7に記載のキャリア。
[請求項9]
請求項5~8のいずれか一項に記載のキャリアと生理活性物質とを備えることを特徴とする医薬組成物。
[請求項10]
膵癌治療用又は診断用である請求項9に記載の医薬組成物。
  • Applicant
  • ※All designated countries except for US in the data before July 2012
  • NIIGATA UNIVERSITY
  • Inventor
  • KONDO Eisaku
  • SAITO Ken
IPC(International Patent Classification)
Specified countries National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
Please contact us by E-mail or facsimile if you have any interests on this patent.

PAGE TOP

close
close
close
close
close
close